The Schall Law Firm announced it is investigating The Clorox Company (NYSE: CLX) for securities law violations, adding to the legal pressure on the consumer goods maker already facing a similar probe from Pomerantz LLP.
The investigations concern whether Clorox and its leadership engaged in securities fraud or other unlawful business practices by issuing false statements or failing to disclose crucial information. On April 30, 2026, Clorox disclosed that its gross margin had decreased and lowered its full-year fiscal 2026 gross margin outlook, expecting a decline of 250 to 300 basis points.
Following the April announcement, Clorox's stock price fell $9.33 per share, or 9.67%, to close at $87.11 on May 1, 2026. The stock is down 30.1% over the past year, with longer-term holders facing a 40.2% decline over five years as the company struggles with the integration of its GOJO (Purell) acquisition and a costly ERP system rollout.
The legal scrutiny intersects with a difficult operational period for Clorox, amplifying investor concerns about the sustainability of its dividend. With a current yield of 5.7%, analysts have noted that the dividend and debt are not well covered by cash flows, a situation made more precarious by the new legal challenges and heightened competition from peers like Procter & Gamble and Colgate-Palmolive.
The Schall Law Firm’s investigation, announced May 11, focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. This follows a similar investigation by Pomerantz LLP, which is looking into claims on behalf of investors following the company's third-quarter financial report and subsequent stock drop. During the company's earnings call, Clorox attributed the lower-than-expected gross margin to supply chain costs and delayed savings as it prioritized stabilizing its new ERP system.
The investigations land amid a complex financial picture for Clorox. The company recently lowered its fiscal 2026 diluted EPS guidance by 24% to 27%, to a range between US$4.78 and US$4.98. To manage its finances, Clorox recently issued several tranches of senior unsecured notes totaling over US$1.5 billion to refinance existing debt. While this extends debt maturities, it also locks in fixed interest costs for years, putting further pressure on a balance sheet already strained by operational headwinds.
The mounting legal challenges could divert management focus and resources from critical operational turnarounds, potentially delaying any recovery and further pressuring the dividend. Investors will be watching for the company's official response and any filings related to the class action suits.
This article is for informational purposes only and does not constitute investment advice.
